Posted on

Is LSD the new Adderall?

MindMed Initiates Phase 2a LSD Trial for the Treatment of Adult ADHD

MindMed (MNMD) is collaborating with universities in Switzerland and the Netherlands to study the effects of microdosing LSD on adults with ADHD. Patients will be assessed on symptoms of inattention, impulsivity, and hyperactivity after microdosing twice a week for six weeks. 

“The study builds on the growing evidence demonstrating LSD has the potential to improve mood and selective cognitive processes,” says the company’s new CEO, Robert Barrow, who was appointed this week.

PDF of article

Posted on

How psychedelics change your social life

How Do Psychedelics Change Your Personality? These Researchers Tried To Find Out

Researchers developed a personality model to test how psychedelics affect the qualities that help us build and maintain healthy relationships.

They discovered that after taking psychedelics, participants felt:

  • Less critical in their interactions with others,
  • Less anxious,
  • Less likely to get upset easily,
  • Greater feelings of social connectedness

How do you see psychedelics changing your relationships?

PDF of article

Posted on

New microdosing patch for autistic patients

Nova Mentis and Mycrodose Therapeutics Announce Major Milestone with Transdermal Technology for Fragile X Syndrome Clinical Program

Nova Mentis (NOVA) and Mycrodose Therapeutics successfully created a transdermal patch that delivers Nova’s psilocybin formulation through the skin. The companies aim to use the patch to administer microdoses to autistic patients to treat cognitive impairments.

This method could be administered at home to reduce medical costs for families and save time for overworked medical professionals.

PDF of article

Novamentis
Posted on

MINDCURE Announces Certification of HIPAA Compliance, Bringing iSTRYM Closer to Commercial Deployment in the Second Quarter of 2022

MINDCURE Announces Certification of HIPAA Compliance, Bringing iSTRYM Closer to Commercial Deployment in the Second Quarter of 2022

MINDCURE’s (MCUR) digital therapeutics platform was certified as HIPAA compliant, meaning that it effectively protects sensitive patient data. The certification gets the company one step closer to commercially deploying the platform in Q2 of 2022.

PDF of article

Posted on

Doseology Prepares to Expand Mushroom Production by Hiring Dr. Wellman-Labadie to Oversee Planned Research and Development Laboratory

Doseology Prepares to Expand Mushroom Production by Hiring Dr. Wellman-Labadie to Oversee Planned Research and Development Laboratory

Doseology Sciences Inc. (MOOD), a functional mushroom company, is preparing to expand into the psilocybin market with a recent application for a controlled substance Dealer’s License and a new addition to its research team. The company aims to develop and sell novel strains of psychedelic mushrooms once granted the license. 

PDF of article

(CNW Group/Doseology Sciences Inc.)
Posted on

New York could be the next state to legalize psilocybin therapy

New York Lawmaker Files Bill To Legalize Medical Psilocybin Treatments, With Focus On First Responders And Veterans

New York assemblyman Pat Burke (D) filed a bill that would legalize psilocybin therapy and create a $2M grant program to ensure veterans and first responders can access the treatment.

If passed, therapists would be able to certify patients for psilocybin therapy after completing a two-hour training course through the Department of Health.

PDF of article

Posted on

A better solution for cancer patients

B.C.’s functional and psychedelic mushroom industry is having a shroom boom

Antidepressants are often ineffective and can even interfere with cancer treatment drugs.

“Psychedelics are proving to not conflict with the cancer drug and are more effective than normal antidepressants generally,” according Frank Lane, director of Albert Labs. 

That’s why the BC-based company wants to bring a psilocybin treatment for cancer patients to European markets.

Albert Labs is expected to begin trading on the CSE early next year under the ticker ’ABRT’.

PDF of article

Posted on

You no longer have to be on your deathbed to eat mushrooms!

Exclusive: Three Canadians with mental health conditions receive legal access to psilocybin mushrooms

Up until this week, the only people in Canada that could legally access psilocybin therapy were patients with terminal illnesses. 

Things changed on Monday, when the non-profit organization TheraPsil helped three Canadians with mental health issues get Section 56 exemptions, granting them access to psilocybin therapy.

“This is a very clear indication that exemptions are now available for people who have anxiety, depression, addiction, and chronic pain,” says TheraPsil’s CEO. “It opens it up to everyone.”

PDF of article